Improved glycaemic control by switching from insulin NPH to insulin glargine: A retrospective observational study

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Sharplin, Peter ^a   Gordon, Jason ^a   Peters, John R ^b   Tetlow, Anthony P ^a   Longman, Andrea J ^a   McEwan, Philip ^a  

^a CHKS Health Economics Unit   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; RELIABILITY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT CHANGE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ADULT; BODY WEIGHT; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN, NPH; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 60849128523     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-3     Document Type: Article

References (48)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus NEJM 1993, 329:977-986 10.1056/NEJM199309303291401 8366922
2. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998, 352:837-853 10.1016/S0140-6736(98)07019-6 9742976
3. National Institute for Health and Clinical Excellence The management of type 2 diabetes (update) (Clinical guideline 66.) London: NICE 2008 http://www.nice.org.uk/Guidance/CG66
4. National Institute for Health and Clinical Excellence Diagnosis and management of type 1 diabetes in children, young people and adults (Clinical guideline 15.) London: NICE 2004 http://www.nice.org.uk/ guidance/index.jsp?action=byID&o=10944
5. IDF Clinical Guidelines Task Force Global Guideline for type 2 Diabetes: recommendations for standard, comprehensive, and minimal care Diabet Med 2006, 23:579-593 10.1111/j.1464-5491.2006.01918.x 16759299
6. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus Endocr Pract 2007, 13(Suppl 1):1-68 17613449
7. American Diabetes Association Standards of medical care in diabetes - 2008 Diabetes Care 2008, 31(Suppl 1):S12-54 10.2337/dc08-S012 18165335
8. Department of Health Diabetes National Service Framework Guidelines http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Diabetes/ index.htm
9. Nathan DM Buse JB Davidson MB Ferrannini E Holman RR Sherwin R Zinman B Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2008, 31(12):1-11 18165348
10. Heinemann L Linkeschova R Rave K Hompesch B Sedlak M Heise T Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 2000, 23:644-649 10.2337/diacare.23.5.644 10834424
11. Rosenstock J Dailey G Massi-Benedetti M Fritsche A Lin Z Salzman A Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care 2005, 28:950-955 10.2337/diacare.28.4.950 15793205
12. Horvath K Jeitler K Berghold A Ebrahim SH Gratzer TW Plank J Kaiser T Pieber TR Siebenhofer A Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus Cochrane Database Syst Rev 2007, CD005613 17443605
13. Ratner RE Hirsch IB Neifing JL Garg SK Mecca TE Wilson CA Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes Diabetes Care 2000, 23:639-643 10.2337/diacare.23.5.639 10834423
14. Wang F Carabino JM Vergara CM Insulin glargine: A systematic review of a long-acting insulin analogue Clin Ther 2003, 25:1541-77 10.1016/ S0149-2918(03)80156-X 12860485
15. Pieber TR Eugene-Jolchine I Derobert E Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes Diabetes Care 2000, 23:157-162 10.2337/diacare.23.2.157 10868824
16. Witthaus E Stewart J Bradley C Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes Diabet Med 2001, 18:619-625 10.1046/j.1464-5491.2001.00529.x 11553198
17. Mullins P Sharplin P Yki-Jarvinen H Riddle MC Haring HU Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus Clin Ther 2007, 29:1607-1619 10.1016/ j.clinthera.2007.08.020 17919543
18. Cramer JA Pugh MJ The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin? Diabetes Care 2005, 28:78-83 10.2337/diacare.28.1.78 15616237
19. Lee WC Balu S Cobden D Joshi AV Pashos CL Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data Clin Ther 2006, 28:1712-1725 10.1016/ j.clinthera.2006.10.004 17157128
20. Fischer JS McLaughlin T Loza L Beauchamp R Schwartz S Kipnes M The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: An office-based naturalistic study Curr Med Res Opin 2004, 20:1703-1710 10.1185/ 030079904X5526 15537471
21. Garg SK Gottlieb PA Hisatomi ME D'Souza A Walker AJ Izuora KE Chase HP Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine Diabetes Res Clin Pract 2004, 66:49-56 10.1016/j.diabres.2004.02.008 15364161
22. Schreiber SA Schneider K Schweitzer MA Haak T German-general practioner-lantus-insulin-study: German observational cohort study of basal support oral therapy with insulin glargine Diabetes und Stoffwechsel 2005, 14:13-18
23. Erickson TN Devine EB O'Young TS Hanson LJ French B Brennan C Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine Am J Health Syst Pharm 2006, 63:1862-1871 10.2146/ajhp050439 16990633
24. Siegmund T Weber S Blankenfeld H Oeffner A Schumm-Draeger PM Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin Exp Clin Endocrinol Diabetes 2007, 115:349-353 10.1055/ s-2007-973082 17701878
25. Bourke A Dattani H Robinson M Feasibility study and methodology to create a quality-evaluated database of primary care data Inform Prim Care 2004, 12:171-177 15606990
26. Poole CD Tetlow T McEwan P Holmes P Currie CJ The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis Curr Med Res Opin 2007, 23:S41-S48 10.1185/030079907X167589
27. Currie CJ Poole CD Tetlow T Holmes P McEwan P The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis Curr Med Res Opin 2007, 23:S33-S39 10.1185/030079907X167534
28. Brown PJ Warmington V Laurence M Prevost AT Randomised crossover trial comparing the performance of Clinical Terms Version 3 and Read Codes 5 byte set coding schemes in general practice BMJ 2003, 326:1127 156010 12763986 10.1136/bmj.326.7399.1127
29. Gallen I Carter C Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes Pract Diab Int 2004, 21:110-114 10.1002/pdi.604
30. Maia FF Melo FJ Araujo IM Araujo LR [Switching of NPH insulin to glargine therapy in a cohort of poorly controlled diabetic patients: observational study]. [Portuguese] Arq Bras Endocrinol Metab 2007, 51:426-430
31. Hammer H Klinge A Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice Int J Clin Pract 2007, 61:2009-2018 2228388 17997807 10.1111/ j.1742-1241.2007.01598.x
32. Schreiber SA Haak T Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: An observational study of everyday practice in 12,216 patients Diabetes Obes Metab 2007, 9:31-38 10.1111/j.1463-1326.2006.00593.x 17199716
33. Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Hadden D Turner RC Holman RR Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 2000, 321:405-412 27454 10938048 10.1136/ bmj.321.7258.405
34. Benedetti M Humburg E Dressler A Ziemen M A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes Horm Metab Res 2003, 35:189-196 10.1055/s-2003-39080 12734781
35. Albright ES Desmond R Bell DS Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy Diabetes Care 2004, 27:632-633 10.2337/diacare.27.2.632 14747268
36. Stroup J Kane MP Busch RS Bakst G Hamilton RA The utility of insulin glargine in the treatment of diabetes mellitus Pharmacotherapy 2004, 24:736-742 10.1592/phco.24.8.736.36064 15222663
37. Hamann A Matthaei S Rosak C Silvestre L A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes Diabetes Care 2003, 26:1738-1744 10.2337/diacare.26.6.1738 12766103
38. Fritsche A Schweitzer MA Haring HU Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: A randomized, controlled trial Ann Intern Med 2003, 138:952-959 12809451
39. Krapek K King K Warren SS George KG Caputo DA Mihelich K Holst EM Nichol MB Shi SG Livengood KB Walden S Lubowski TJ Medication adherence and associated hemoglobin A1c in type 2 diabetes Ann Pharmacother 2004, 38:1357-1362 10.1345/aph.1D612 15238621
40. Rhee MK Slocum W Ziemer DC Culler SD Cook CB El Kebbi IM Gallina DL Barnes C Phillips LS Patient adherence improves glycemic control Diabetes Educ 2005, 31:240-250 10.1177/0145721705274927 15797853
41. Benson K Hartz AJ A comparison of observational studies and randomized, controlled trials NEJM 2000, 342:1878-1886 10.1056/NEJM200006223422506 10861324
42. Concato J Shah N Horwitz RI Randomized, controlled trials, observational studies, and the hierarchy of research designs NEJM 2000, 342:1887-1892 1557642 10861325 10.1056/NEJM200006223422507
43. Woehl A Evans M Tetlow AP McEwan P Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom Cardiovasc Diabetol 2008, 7:24 2546382 18694484 10.1186/1475-2840-7-24
44. McEwan P Mehin N Ap T Sharplin P The relative cost effectiveness of insulin glargine versus NPH insulin using UK real life data in patients with type 2 diabetes mellitus [abstract] Value Health 2007, 10:A64-A65 10.1111/j.1524-4733.2007.00268.x
45. Raccah D Bretzel RG Owens D Riddle M When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? Diabetes Metab Res Rev 2007, 23:257-264 10.1002/dmrr.733 17315242
46. Schreiber SA Russmann A The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice Curr Med Res Opin 2006, 22:335-341 10.1185/ 030079906X80468 16466605
47. Schreiber SA Russmann A Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice Curr Med Res Opin 2007, 23:3131-3136 10.1185/030079907X242827 17988433
48. Davies M Sinnassamy P Storms F Gomis R Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies Diabetes Res Clin Pract 2008, 79:368-375 10.1016/j.diabres.2007.09.013 17980928